Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 13, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the third quarter of 2024 and provided a business update.</li><li>The company announced positive topline results for the six-month Phase 2 trial of mavorixafor in patients with chronic neutropenia (CN).</li><li>The drug raised participants mean absolute neutrophil counts (ANC), and physicians were able to reduce G-CSF dosing in nine of 12 eligible patients, with three taken off G-CSF completely.</li></ul>

On November 13, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the third quarter of 2024 and provided a business update.The company announced positive topline results for the six-month Phase 2 trial of mavorixafor in patients with chronic neutropenia (CN).The drug raised participants mean absolute neutrophil counts (ANC), and physicians were able to reduce G-CSF dosing in nine of 12 eligible patients, with three taken off G-CSF completely.

XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia 